ABL1 antibody (C-Abl Oncogene 1, Non-Receptor tyrosine Kinase) (pTyr134)

Details for Product anti-ABL1 Antibody No. ABIN389501, Supplier: Log in to see
Antigen
  • ABL1
  • ABL
  • CABL
  • ABLL
  • cb272
  • JTK7
  • bcr/abl
  • c-ABL
  • p150
  • v-abl
  • AI325092
  • Abl
  • E430008G22Rik
  • c-Abl
  • MTP
  • c-abl oncogene 1, receptor tyrosine kinase
  • c-abl oncogene 1, non-receptor tyrosine kinase
  • v-abl Abelson murine leukemia viral oncogene homolog 2
  • microsomal triglyceride transfer protein
  • Protein ABL-1
  • ABL1
  • ABL2
  • abl2
  • Abl1
  • MTTP
  • abl-1
Alternatives
anti-Human ABL1 antibody for Dot Blot
Epitope
pTyr134
53
52
43
31
28
27
24
16
16
16
16
16
15
15
15
15
15
15
15
15
11
10
8
8
7
7
6
6
6
6
5
4
3
3
3
3
3
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Reactivity
Human
615
405
317
10
4
3
1
1
1
1
Host
Rabbit
613
23
Clonality (Clone)
Polyclonal ()
Conjugate
This ABL1 antibody is un-conjugated
32
31
29
16
16
16
15
15
15
15
15
15
15
15
15
15
15
1
Application
Dot Blot (DB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
363
195
189
161
120
68
43
25
15
11
6
2
2
1
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Available images

Immunogen This ABL1 Antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding Y134 of human ABL1.
Clone RB7343
Isotype Ig
Specificity This Phospho-ABL1-Y134 antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding Y134 of human ABL1.
Predicted Reactivity Mouse (Murine)
Purification This antibody is purified through a protein A column, followed by peptide affinity purification.
Alternative Name ABL1 (ABL1 Antibody Abstract)
Background ABL1 is a cytoplasmic and nuclear protein tyrosine kinase that has been implicated in processes of cell differentiation, cell division, cell adhesion, and stress response. Activity of c-Abl protein is negatively regulated by its SH3 domain, and deletion of the SH3 domain turns ABL1 into an oncogene. The t(9,22) translocation results in the head-to-tail fusion of the BCR and ABL1 genes present in many cases of chronic myelogeneous leukemia. The DNA-binding activity of the ubiquitously expressed ABL1 tyrosine kinase is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function for ABL1.
Synonyms: Proto-oncogene tyrosine-protein kinase ABL1, p150, c-ABL, Abelson murine leukemia viral oncogene homolog 1, ABL1, ABL, JTK7,
Molecular Weight 122873 DA
Gene ID 25
UniProt P00519
Research Area Apoptosis/Necrosis, Phospho-specific antibodies, Cell Signaling, Protein Modifications, Cancer, Cell Cycle, Cell Structure
Pathways Apoptosis, Regulation of Muscle Cell Differentiation, Platelet-derived growth Factor Receptor Signaling
Application Notes DB = 1:500, IHC (p) = 1:50-100
Restrictions For Research Use only
Format Liquid
Concentration 0.35 mg/mL
Buffer PBS with 0.09 % (W/V) sodium azide
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C/-20 °C
Storage Comment Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
Expiry Date 6 months
Supplier Images
Dot Blot (DB) image for anti-ABL1 antibody (C-Abl Oncogene 1, Non-Receptor tyrosine Kinase) (pTyr134) (ABIN389501) Dot blot analysis of anti-Phospho-ABL1-Y134 Antibody (ABIN389501) on nitrocellulose m...
Immunohistochemistry (IHC) image for anti-ABL1 antibody (C-Abl Oncogene 1, Non-Receptor tyrosine Kinase) (pTyr134) (ABIN389501) Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary ant...
Product cited in: Asmussen, Lasater, Tajon, Oses-Prieto, Jun, Taylor, Burlingame, Craik, Shah: "MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction." in: Cancer discovery, Vol. 4, Issue 2, pp. 200-15, 2014 (PubMed).

Background publications Barnes, McIntosh, Whetton, Daley, Bentley, Baldwin: "Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation." in: Oncogene, Vol. 24, Issue 20, pp. 3257-67, 2005 (PubMed).

Kim, Cho, Yoon, Park, Kim, Lee, Chun, Kim, Lee et al.: "Interpretation of submicroscopic deletions of the BCR or ABL gene should not depend on extra signal-FISH: problems in interpretation of submicroscopic deletion of the BCR or ABL gene with extra ..." in: Genes, chromosomes & cancer, Vol. 43, Issue 1, pp. 37-44, 2005 (PubMed).

Aichberger, Mayerhofer, Krauth, Skvara, Florian, Sonneck, Akgul, Derdak, Pickl, Wacheck, Selzer, Monia, Moriggl, Valent, Sillaber: "Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides." in: Blood, Vol. 105, Issue 8, pp. 3303-11, 2005 (PubMed).

Wei, Li, Liu: "Insights into selective activation of p53 DNA binding by c-Abl." in: The Journal of biological chemistry, Vol. 280, Issue 13, pp. 12271-8, 2005 (PubMed).

Robinson, Martineau, Harris, Barber, Jalali, Moorman, Strefford, Broadfield, Cheung, Harrison: "Derivative chromosome 9 deletions are a significant feature of childhood Philadelphia chromosome positive acute lymphoblastic leukaemia." in: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, Vol. 19, Issue 4, pp. 564-71, 2005 (PubMed).